Immunomodulation of cells from myeloid lineage as a therapy

摘要

This notification concerns the way in which myeloid line cancer cells increase their activity, including contact steps of myeloid line cells with Toll-like receptor agonist (TLR) and cell determinant receptor agonist 200 (CD200R). The notification shall also cover cells which may be produced by the way and pharmaceutical composition containing cells and the use of such cells or pharmaceutical composition containing cells as medicinal products,and in particular for the treatment of cancer. The notification also concerns a set comprising a TLR agonist and a CD200R agonist. It also concerns a pharmaceutical composition containing a TLR agonist and a CD200R agonist.